EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Growth hormone therapy in normal short children induces a transitory decrease in plasma growth hormone releasing hormone levels and in human growth hormone responsiveness to exogenous growth hormone releasing hormone



Growth hormone therapy in normal short children induces a transitory decrease in plasma growth hormone releasing hormone levels and in human growth hormone responsiveness to exogenous growth hormone releasing hormone



Journal of Endocrinological Investigation 15(10): 735-739



A three-month study of the effect of growth hormone (hGH) therapy (0.1 U/kg/day sc) on plasma levels of GH releasing hormone (GHRH), somatostatin and insulin-like growth factor I (IGF-I) and on the hGH responsiveness to exogenous GHRH was carried out in 32 prepubertal short-stature children with normal GH secretion. Blood samples were collected prior to initiation of therapy, and at 5, 30 and 90 days of onset of therapy, as well as 2 and 90 days after termination of therapy. The nonconventional hGH therapy induced an increase in serum IGF-I levels which lasted as long as therapy was continued. Plasma GHRH levels showed an early transitory decrease after five days of therapy, whereas plasma somatostatin levels were unaltered. A slight suppression in hGH responsiveness to exogenous GHRH was found at 2 but not at 90 days after termination of hGH therapy. It is concluded that nonconventional hGH treatment does not cause permanent changes in physiological hGH secretion.

Accession: 008747625

Download citation: RISBibTeXText

PMID: 1362733

DOI: 10.1007/BF03347642

Download PDF Full Text: Growth hormone therapy in normal short children induces a transitory decrease in plasma growth hormone releasing hormone levels and in human growth hormone responsiveness to exogenous growth hormone releasing hormone



Related references

Effect of growth hormone releasing hormone on plasma growth hormone in relation to magnitude and duration of growth hormone deficiency in 26 children and adults with isolated growth hormone deficiency or multiple pituitary hormone deficiencies evidence for hypothalamic growth hormone releasing hormone deficiency. Journal of Clinical Endocrinology & Metabolism 58(6): 1043-1049, 1984

Growth hormone releasing hormone sensitive adenylate cyclase activity in growth hormone producing pituitary adenoma correlation to the response of plasma growth in hormone to growth hormone releasing hormone in patients with acromegaly. Endocrinologia Japonica 36(2): 229-236, 1989

Pulsatile growth hormone releasing hormone treatment can induce growth hormone and somatomedin c responses in growth hormone deficient children initially unresponsive to single bolus growth hormone releasing hormone. Pediatric Research 20(4 PART 2): 217A, 1986

Combined growth hormone-releasing hormone and growth hormone-releasing peptide-6 test for the evaluation of growth hormone secretion in children with growth hormone deficiency and growth hormone neurosecretory dysfunction. Hormone Research 70(4): 215-223, 2008

Intravenous growth hormone releasing hormone 1 40 studies do not predict the growth hormone response to long term subcutaneous growth hormone releasing hormone treatment of growth hormone deficient children. Journal of Endocrinology 108(SUPPL), 1986

Evidence for a limited growth hormone releasing hormone releasable quantity of growth hormone effects of 6 hour infusions of growth hormone releasing hormone on growth hormone secretion in normal man. Journal of Clinical Endocrinology & Metabolism 60(2): 370-375, 1985

Plasma growth hormone response to human pancreatic growth hormone releasing factor 44 in normal children of short stature and patients with growth hormone deficiency. Endocrinologia Japonica 31(1): 41-48, 1984

Previous beta adrenergic blockade increases growth hormone response to growth hormone releasing hormone 29 in short normal but not in growth hormone deficient children. Pediatric Research 20(11): 1190, 1986

Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion. Endocrine 14(1): 79-86, 2001

Role of selected endogenous peptides in growth hormone-releasing hexapeptide activity: analysis of growth hormone-releasing hormone, thyroid hormone-releasing hormone, and gonadotropin-releasing hormone. Endocrinology 130(5): 2579-2586, 1992

Circulating immunoreactive growth hormone releasing hormone concentrations and growth hormone response to growth hormone releasing hormone in short children. European Journal Of Pediatrics. 152(12): 984-989, 1993

Growth hormone responses to growth hormone releasing hormone during pubertal development in normal boys and girls comparison to idiopathic short stature and growth hormone deficiency. Journal of Clinical Endocrinology & Metabolism 63(1): 174-179, 1986

Effects of pulsatile administration of growth hormone growth hormone releasing hormone on short term linear growth in children with growth hormone deficiency. Journal of Clinical Endocrinology & Metabolism 61(3): 444-450, 1985

Is the growth outcome of children with idiopathic short stature and isolated growth hormone deficiency following treatment with growth hormone and a luteinizing hormone-releasing hormone agonist superior to that obtained by GH alone?. Journal of Pediatric Endocrinology & Metabolism 25(7-8): 651-657, 2013

Atenolol enhances growth hormone release to exogenous growth hormone-releasing hormone but fails to alter spontaneous nocturnal growth hormone secretion in boys with constitutional delay of growth. Pediatric Research 23(4): 393-397, 1988